• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Pluristem Life Systems Hires American Capital Ventures to Provide Investor Relations Services

Posted on: Tuesday, 19 June 2007, 09:01 CDT

Pluristem Life Systems, Inc. (OTCBB:PLRS)(DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that it has hired American Capital Ventures, Inc. to provide investor relations services in an effort to bring greater investor awareness to the company.

American Capital Ventures, Inc. ("ACV") is a company comprised of industry professionals with over 45 years of collective experience in the brokerage and investor relations industries. ACV President Howard Gostfrand stated, "We are pleased to be able to spearhead Pluristem's efforts to bring their financial story to the investment community. Their potential market is enormous and we are highly confident in management's ability to be a leader in their space."

"At this stage in Pluristem's growth we are excited to be able to cede the responsibilities of investor relations to such a professional group. Hiring ACV will give us the chance to truly focus on our business. Pluristem is making great progress and we are thrilled to be able to have our story presented to a wider audience," said Zami Aberman, Chairman and CEO of Pruristem.

About Pluristem Life Systems, Inc.

Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).

Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.

Pluristem has offices and is incorporated in the USA with research and manufacturing facilities in Israel. www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

Source: Business Wire

More News in this Category